- Recce Pharmaceuticals (RCE) sees its clinical trial receive a good safety profile among ten healthy male subjects
- The company reported its drug, R327, demonstrated a good tolerability profile among ten male subjects who were intravenously dosed at 2,000 milligrams (mg)
- As such, an independent safety committee has unanimously approved the next cohort to begin dosing at 4,000mg, with subjects now recruited and dosing underway
- The company says the study is on track to have all phase one dosing complete by the second quarter of 2022
- Recce Pharmaceuticals is up 3.07 per cent, trading at 84 cents at 12:39 pm AEST
Recce Pharmaceuticals (RCE) has seen its clinical trial receive a good safety profile among ten healthy male subjects.
The company has been working to develop a new class of synthetic anti-infectives. Today it reported its drug, R327, demonstrated a good tolerability profile among ten male subjects who were intravenously dosed at 2,000 milligrams (mg).
As such, an independent safety committee has unanimously approved the next cohort to begin dosing at 4,000mg, with subjects now recruited and dosing underway.
The trial is a randomised, placebo-controlled, single-dose study evaluating the safety and pharmacokinetics of R327 in up to ten healthy subjects per dose, across eight sequential dosing cohorts.
R327 is said to be the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.
The company says the study is on track to have all phase one dosing complete by the second quarter of 2022.
“This data builds on previous cohorts and validates RECCE 327’s compelling safety and tolerability profile, with the potential to serve as a solution for patients with sepsis,” CEO James Graham said.
“We are greatly encouraged by this progress and moved quickly to commence dosing of Cohort 6, evaluating R327 in high doses of 4,000mg.”
Recce Pharmaceuticals was up 3.07 per cent, trading at 84 cents at 12:39 pm AEST.